| payload |
{"created_at":"2026-04-21T03:09:54.871 {"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:66080cbab2837a68","evidence_event_ids":["evt_1b2145a1e8a3"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000035.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000035.txt","company":"UNITED THERAPEUTICS Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000035.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_d81956ec0c3aaf8a","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000035.txt","content_type":"text/plain","enriched_at":"2026-04-21T06:14:53.451533+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000035.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000035.txt","source_event_id":"evt_1b2145a1e8a3","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"38ba8f7801a38270","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-20","2026-04-17","2025-11-07","2027-03-17","2026-12-31"],"entities":[{"asset_class":"equity","name":"UNITED THERAPEUTICS Corp","relevance":"high","symbol":"UTHR","type":"issuer"},{"asset_class":"equity","name":"Martine A. Rothblatt","relevance":"high","symbol":"","type":"reporting_person"}],"event_type":"listing","information_gaps":["The provided text does not clearly specify the total number of shares bought/sold in aggregate; it lists multiple line items but the aggregate totals are not explicitly consolidated in the excerpt.","The excerpt includes many repeated/fragmented lines (e.g., multiple weighted-average price statements) without a clear mapping of each price range to a specific share quantity in the provided text.","The signal type is labeled as discovery_sec_filing_delta, but the prior known state/delta versus earlier filings is not provided in the prompt, so the exact change from prior state cannot be determined from this input alone."],"key_facts":["SEC filing: Form 4 (SEC Act: 1934 Act), issuer United THERAPEUTICS Corp (CIK 0001082554).","Filed as of date: 2026-04-20; conformed period of report: 2026-04-17.","Reporting owner: Martine A. Rothblatt (CIK 0001106578).","The filing states the exercise of stock options and sale of resulting common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.","The plan is stated to continue until the earlier of: (a) exercise of 1,734,410 stock options (all expire March 17, 2027) or (b) December 31, 2026.","The filing states the transaction was executed in multiple trades at prices ranging from $587.93 to $588.92 (weighted average price reported).","The filing further states multiple trade price ranges in subsequent lines: $588.93 to $589.92; $589.93 to $590.92; $590.93 to $591.12; and $592.22 to $592.43 (each with weighted average price language)."],"numeric_claims":[{"label":"Form 4 filed as of date","value":"2026-04-20"},{"label":"Conformed period of report","value":"2026-04-17"},{"label":"10b5-1 plan adoption date","value":"2025-11-07"},{"label":"Plan end condition (options to be exercised)","value":"1,734,410 stock options"},{"label":"Options expiration date","value":"2027-03-17"},{"label":"Plan end condition (date)","value":"2026-12-31"},{"label":"Trade price range (one stated range)","value":"$587.93 to $588.92"},{"label":"Trade price range (another stated range)","value":"$592.22 to $592.43"}],"primary_claim":"Form 4 for United Therapeutics (UTHR) was filed on 2026-04-20 (covering 2026-04-17) by Martine A. Rothblatt, and the transactions were executed pursuant to a 10b5-1 trading plan adopted on 2025-11-07.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"United Therapeutics (UTHR) reported a Form 4 filed on 2026-04-20 covering transactions by reporting person Martine A. Rothblatt for the period ending 2026-04-17. The filing states the activity was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, involving exercise of stock options and sale of resulting shares at prices around the high-$500s/low-$590s.","topics":["SEC Form 4","insider trading","10b5-1 trading plan","stock option exercise","sale of common stock"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 UNITED THERAPEUTICS Corp \u00b7 Filed 20260420","ticker":"UTHR","tickers":["UTHR"],"title":"UTHR filed 4","url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000035.txt"}}... |